Clinical Trial Update: A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment

View source ↗

Summary

A completed post-marketing surveillance study evaluating cetuximab (Erbitux) in patients with metastatic colorectal cancer refractory to irinotecan-containing t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Metastatic Colorectal Cancer | Status: COMPLETED